



ATTORNEY DOCKET NO. 1703-007.US1

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

**Applicants** : Afar et al.  
**Serial No** : 09/323,597  
**Filed** : June 1, 1999  
**For** : NOVEL PROSTATE TUMOR ANTIGEN USEFUL IN DIAGNOSIS AND  
THERAPY OF PROSTATE AND COLON CANCERS

Point Reyes, December 22, 1999

Assistant Commissioner for Patents  
Box Sequence  
Washington, D.C. 20231

SIR:

**COMMUNICATION IN RESPONSE TO NOTICE TO COMPLY  
WITH REQUIREMENTS FOR PATENT APPLICATIONS  
CONTAINING NUCLEOTIDE SEQUENCE AND/OR  
AMINO ACID SEQUENCE DISCLOSURES**

This Communication is submitted in response to a Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures issued June 25, 1999 in connection with the above-identified application. Applicants hereby submit original documents, including a disk consisting of the Sequence Listing in computer readable form pursuant to 37 C.F.R. §1.821 – 1.825. A Declaration pursuant to 37 C.F.R. §1.821(f), and a Preliminary Amendment directing the entry of the Sequence Listing into the specification of the above-referenced application, are filed concurrently herewith. No fee is deemed necessary in connection with the filing of this Communication.

Respectfully submitted,

Kenneth K. Sharples  
Registration No. 35,355  
Attorney for Applicants

Law Office of Kenneth K. Sharples  
80 Fourth Street, Suite 202  
P.O. Box 277  
Point Reyes Station, California 94956  
415/663-0323



# 5

ATTORNEY DOCKET NO. 1703-007.US1

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

**Applicants** : Danny E. Afar et al.  
**Serial No** : 09/323,597  
**Filed** : June 1, 1999  
**For** : NOVEL PROSTATE TUMOR ANTIGEN USEFUL IN  
DIAGNOSIS AND THERAPY OF PROSTATE AND COLON  
CANCERS

Point Reyes, December 22, 1999

Assistant Commissioner for Patents  
Box Sequence  
Washington, D.C. 20231

SIR:

**DECLARATION PURSUANT TO 37 C.F.R. §1.821(f)**

In accordance with the provisions of 37 C.F.R. §1.821(f), I hereby declare that the content of the paper and computer readable copies of the Sequence Listing, submitted December 22, 1999 in connection with the subject patent application (37 C.F.R. §1.821(c) and (e), respectively), are identical and include no new matter.

Respectfully submitted,

Kenneth K. Sharples  
Registration No. 35,355  
Attorneys for Applicants  
Law Office of Kenneth K. Sharples  
80 Fourth Street, Suite 202  
P.O. Box 277  
Point Reyes Station, California 94956  
415/663-0323



UNITED STATES DEPARTMENT OF COMMERCE  
Patent and Trademark Office  
Address: COMMISSIONER OF PATENTS AND TRADEMARK  
Washington, D.C. 20231

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NO./TITLE
09/323,597	06/01/99	AFAR	D. 1703-007, US1

0232/0625  
LAW OFFICE OF KENNETH K. SHARPLES  
P O BOX 277  
80 FOURTH STREET  
POINT REYES STATION CA 94956



NOT ASSIGNED

1643  
DATE MAILED:

06/25/99

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS  
CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821 - 1.825 for the following reason(s):

- ☒ 1. This application fails to comply with the requirements of 37 CFR 1.821 - 1.825.
- ☐ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 CFR 1.821(c).
- ☐ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e).
- ☐ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. The content of the computer readable form, however, does not comply with the requirements of 37 CFR 1.822 and/or 1.832, as indicated on the attached marked-up copy of the "Raw Sequence Listing."
- ☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must be submitted as required by 37 CFR 1.825(d).
- ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 CFR 1.821(e).
- ☐ 7. OTHER: \_\_\_\_\_

**APPLICANT MUST PROVIDE:**

- ☒ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing."
- ☒ An initial or substitute paper copy of the "Sequence Listing," as well as an amendment directing its entry into the specification.
- ☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b) or 1.825(d).

**FOR QUESTIONS REGARDING COMPLIANCE WITH THESE REQUIREMENTS, PLEASE CONTACT:**

- ☐ For Rules Interpretation, call (703) 308-1123.
- ☐ For CRF submission help, call (703) 308-4212.
- ☐ For PatentIn software help, call (703) 308-6856.

*C. Medina*  
Customer Service Center